Arcutis Biotherapeutics Q2 EPS $(1.16) Beats $(1.22) Estimate, Sales $5.19M Beat $4.87M Estimate
Portfolio Pulse from mahesh@benzinga.com
Arcutis Biotherapeutics reported Q2 losses of $(1.16) per share, beating the analyst consensus estimate of $(1.22) by 4.92%. This is an 11.45% increase over losses from the same period last year. The company also reported quarterly sales of $5.19 million, beating the analyst consensus estimate of $4.87 million by 6.57%.
August 08, 2023 | 8:58 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Arcutis Biotherapeutics reported better than expected Q2 earnings and sales, which could positively impact the stock price.
Arcutis Biotherapeutics reported Q2 earnings and sales that beat analyst estimates. This is generally seen as positive news and could lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100